

IMMUNOGENICITY OF V116 (21-VALENT PCV) IN PNEUMOCOCCAL-NAÏVE ADULTS 50–64, 65–74, AND ≥75 YEARS OF AGE: SUBGROUP ANALYSIS OF A RANDOMIZED PHASE 3 TRIAL (STRIDE-3)

bodil Elbrond, Jianing Li

Abstract 379

IMMUNOGENICITY OF V116 (21-VALENT PCV) IN PNEUMOCOCCAL-NAÏVE ADULTS 50–64, 65–74, AND ≥75 YEARS OF AGE: SUBGROUP ANALYSIS OF A RANDOMIZED PHASE 3 TRIAL (STRIDE-3)

Type:

Abstract Submission

Topic:

ASo4 Vaccines – Development, Strategies and Impact / ASo4a New Vaccines and Regulatory Processes

Authors:

Jianing Li

1

,

Christopher Bruno

1

,

Doreen Fernsler

1

,

Leslie Morgan

1

,

Muhammad Waleed

1

,

Heather Platt

2

;

1

Merck Research Laboratories, Merck & Co., Inc., Rahway, NJ, United States of America,

2

Global Clinical Development, Merck & Co., Inc., Rahway, NJ, United States of America

Background

V116 is an investigational PCV containing the most prevalent serotypes associated with pneumococcal disease (PD) in adults in regions with established pediatric vaccination programs. In the Phase 3 STRIDE-3 study (NCT05425732) in adults ≥50 years of age (Cohort 1), V116 was non-inferior to PCV20 for the 10 common serotypes and was superior for 10 of 11 serotypes unique to V116, as measured by opsonophagocytic activity (OPA) geometric mean titers (GMTs) 30 days post-vaccination. The safety profile of V116 was comparable with PCV20. This subgroup analysis of STRIDE-3 evaluated immunogenicity in adults ≥50 years by age groups.